S 
Shenzhen Neptunus Interlong Bio-technique Co 8329.HK · HKD
Health Care · HKEX · 🇭🇰 Hong Kong
0.12
+1.69%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥972.0m
FY2016FY2025
Net income
−CN¥40.7m
FY2016FY2025
Free cash flow
CN¥125.0m
FY2016FY2025
Shareholders' equity
CN¥647.7m
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥972.0m | CN¥892.8m | CN¥1.06bn | CN¥845.7m | CN¥718.9m | CN¥1.03bn | CN¥1.08bn | CN¥867.1m | CN¥790.3m | CN¥759.1m |
| Research and development | CN¥32.7m | CN¥28.4m | CN¥46.2m | CN¥24.6m | CN¥21.6m | CN¥20.2m | CN¥27.8m | CN¥27.3m | CN¥29.4m | CN¥18.1m |
| Operating income | CN¥20.6m | CN¥29.8m | CN¥36.2m | CN¥76.5m | CN¥37.5m | CN¥51.0m | CN¥80.2m | CN¥69.4m | CN¥73.6m | CN¥94.6m |
| Net income | −CN¥40.7m | CN¥21.4m | CN¥24.1m | CN¥46.6m | CN¥30.8m | CN¥36.6m | CN¥59.7m | CN¥48.1m | CN¥50.3m | CN¥62.7m |
| Diluted earnings per share | -0.02 | 0.01 | 0.01 | 0.03 | 0.02 | 0.02 | 0.04 | 0.03 | 0.03 | 0.04 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥1.06bn | CN¥1.20bn | CN¥1.21bn | CN¥1.24bn | CN¥1.12bn | CN¥1.12bn | CN¥1.12bn | CN¥986.1m | CN¥1.00bn | CN¥1.03bn |
| Cash and short-term investments | CN¥209.4m | CN¥242.9m | CN¥327.6m | CN¥300.1m | CN¥266.7m | CN¥415.9m | CN¥384.2m | CN¥323.6m | CN¥350.7m | CN¥325.2m |
| Total liabilities | CN¥352.7m | CN¥318.8m | CN¥342.4m | CN¥379.6m | CN¥311.3m | CN¥225.2m | CN¥264.2m | CN¥187.3m | CN¥250.5m | CN¥334.1m |
| Debt | CN¥73.0m | CN¥90.4m | CN¥76.9m | CN¥79.4m | CN¥90.6m | CN¥10.1m | CN¥43.0m | CN¥9.0m | CN¥39.0m | CN¥109.0m |
| Shareholders' equity | CN¥647.7m | CN¥799.8m | CN¥778.4m | CN¥757.7m | CN¥711.1m | CN¥793.7m | CN¥757.1m | CN¥697.9m | CN¥649.8m | CN¥599.6m |
| Shares outstanding | 1,678m | 1,678m | 1,678m | 1,678m | 1,678m | 1,678m | 1,678m | 1,678m | 1,678m | 1,678m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥139.6m | CN¥20.9m | CN¥53.7m | CN¥52.5m | −CN¥59.9m | CN¥93.6m | CN¥60.4m | CN¥25.0m | CN¥55.8m | CN¥82.9m |
| Capital spending | −CN¥14.6m | −CN¥19.0m | −CN¥15.4m | −CN¥16.9m | −CN¥12.9m | −CN¥38.0m | −CN¥33.5m | −CN¥27.7m | −CN¥12.1m | −CN¥23.6m |
| Free cash flow | CN¥125.0m | CN¥1.9m | CN¥38.3m | CN¥35.6m | −CN¥72.8m | CN¥55.7m | CN¥26.9m | −CN¥2.6m | CN¥43.6m | CN¥59.2m |
| Dividends paid | −CN¥245.0m | — | — | — | — | — | — | — | — | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥430.1m | CN¥218.1m | CN¥238.0m | CN¥238.0m | CN¥248.0m | CN¥248.0m | CN¥213.1m | CN¥248.6m |
| Operating income | CN¥10.0m | CN¥5.8m | −CN¥34.7m | −CN¥34.7m | CN¥12.5m | CN¥12.5m | −CN¥6.9m | −CN¥8.0m |
| Net income | CN¥6.9m | CN¥3.5m | −CN¥29.9m | −CN¥29.9m | CN¥9.5m | CN¥9.5m | −CN¥5.5m | −CN¥6.4m |
| Diluted earnings per share | 0.00 | 0.00 | -0.02 | -0.02 | 0.01 | 0.01 | -0.00 | -0.00 |
| Cash from operations | −CN¥1.0m | — | CN¥96.0m | CN¥49.0m | CN¥20.0m | CN¥20.0m | CN¥1.0m | CN¥1.0m |
| Capital spending | −CN¥3.0m | −CN¥1.0m | −CN¥4.0m | −CN¥2.0m | −CN¥3.0m | −CN¥3.0m | −CN¥2.0m | −CN¥3.0m |
| Free cash flow | −CN¥4.0m | — | CN¥92.0m | CN¥47.0m | CN¥17.0m | CN¥17.0m | −CN¥1.0m | −CN¥2.0m |
| Total assets | CN¥1.07bn | CN¥1.07bn | CN¥1.06bn | CN¥1.06bn | CN¥1.11bn | CN¥1.11bn | CN¥1.20bn | CN¥1.40bn |
| Cash and short-term investments | CN¥212.2m | CN¥212.3m | CN¥209.4m | CN¥209.4m | CN¥139.3m | CN¥139.3m | CN¥242.9m | CN¥283.4m |
| Debt | CN¥95.6m | CN¥94.4m | CN¥73.0m | CN¥70.3m | CN¥101.9m | CN¥96.4m | CN¥90.4m | CN¥100.2m |
| Shareholders' equity | CN¥654.4m | CN¥654.5m | CN¥647.7m | CN¥647.5m | CN¥707.3m | CN¥707.3m | CN¥799.8m | CN¥933.2m |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 4.8% | -1.2% | 3.0% |
| Operating income | -35.5% | -16.6% | -9.6% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | 2.7% | 4.3% | 4.6% | 6.4% |
| Net margin | -1.0% | 1.4% | 2.2% | 3.7% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | -5.8 | 5.7 | 5.1 | 2.8 | 4.5 | 7.1 | 3.0 | 5.5 | 5.5 | 5.8 |
| Price to sales | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 0.3 | 0.2 | 0.3 | 0.3 | 0.5 |
Dividends and splits
Per share, in the currency the company pays
Paid for 1 years. Last went ex-dividend on 15 May 2025.
| FY2025 | |
|---|---|
| Paid in the year | 0.005 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.